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Eosinophils are commonly associated with Th2 cell-driven inflammation. In this issue of Immunity, Griseri
et al. (2015) identify a new GM-CSF-dependent role for eosinophils in the pathogenesis of IL-23-Th17 cell-
induced colitis.Eosinophils are granulocytes that are
critical effector cells of CD4+ T helper
type 2 (Th2) immune responses. They
contribute to protective immunity against
parasites (e.g., helminths) and have path-
ogenic roles in allergic disorders through
the secretion of a broad range of pro-in-
flammatory factors, including cytokines
and chemokines, and through the cyto-
toxic activity of their granule contents. Eo-
sinophils arise from progenitor cells within
the bone marrow, driven to differentiate
by interleukin-3 (IL-3), IL-5, and granulo-
cyte-macrophage colony stimulating fac-
tor (GM-CSF), which signal through a
common b receptor (bc). In healthy indi-
viduals, eosinophils make up over 20%
of the cellularity of small intestinal lamina
propria, and between 1% and 5% of the
circulating peripheral leukocyte popula-
tion. Secretion of IL-5 from Th2 cells dur-
ing episodes of allergic inflammation
stimulates expansion of eosinophils in
the bone marrow and promotes their
release into the circulation. IL-5 also
enhances eosinophil responsiveness to
eotaxins - chemokines that control eosin-
ophil homing to mucosal tissues and
can be upregulated by Th2 cell-type
immune responses (Mould et al., 1997).
Conversely, eotaxins are downregulated
by Th1 cell-type cytokine signaling, via
IFN-g and IL-12. Thus, eosinophil accu-
mulation in tissues is primarily associated
with Th2 type-mediated inflammation. As
such eosinophils are thought to play path-
ogenic roles in asthma, allergic diseases,
and a number of eosinophil-associated
gastrointestinal disorders (EGID) (Jung
and Rothenberg, 2014).
Divergent roles for eosinophils have
been suggested in both homeostasis of
the gastrointestinal tract (GIT) and in thepathogenesis of inflammatory bowel dis-
ease (IBD) (Maltby et al., 2010). This group
of inflammatory diseases of the GIT,
including Crohn’s disease (CD) and ulcer-
ative colitis (UC), are characterized by
chronic mucosal inflammation, resulting
from an immune response to the host’s
normally commensal microbiome, in a
genetically and/or environmentally sus-
ceptible host. The inflammatory profiles
of IBD patients suggest a regulatory
imbalance of granulocytes, antigen-pre-
senting cells, and lymphocytes. There is
substantial inflammatory heterogeneity in
the various IBD subtypes, but CD is
broadly considered a Th1 or Th17 cell dis-
ease, while UC has been defined as an
atypical Th2 cell disease. There are also
similarities in the immunophenotypes of
CD and UC including the loss of IL-22-
mediated homeostasis and IL-23-driven
Th17 cell-mediated inflammation (Ko-
bayashi et al., 2008). The exact role of
eosinophils in the immunopathology of
IBD is unclear. Eosinophils are constitu-
tively present in the GIT and are signifi-
cantly elevated in IBD patients with active
disease. However, although IBD patients
have elevated numbers of degranulated
eosinophils in diseased tissue compared
to healthy subjects, this is also observed
evenwhendisease is inactive. Thus, these
observations have led to the suggestion
that eosinophils might play a role in tissue
repair during the resolution phase of GIT
mucosal inflammation (Lampinen et al.,
2005).
One explanation for these contrasting
observations (pathogenic versus tissue
repair) is that eosinophils are recruited
in the acute phase of colitis through
increases in intestinal eotaxin expression,
where they promote pro-inflammatoryImmuanddiarrheal responses.As IBD inflamma-
tion switches to Th cell-driven responses,
the absence of IL-4 and potentially other
Th2 cell-polarizing factors reduces the
Th2 cell-type immune response and the
role of eosinophils in active inflammation.
This then provides an environment for
them to contribute to wound healing and
fibrosis as inflammation subsides (Mas-
terson et al., 2011). The work by Griseri
et al. (2015), in this issue of Immunity, not
only challenges the perception of eosino-
phils as spectators in chronic IBD inflam-
mation, but goes someway to explaining
the presence and activity of eosinophils
in diseases with immunophenotypes not
normally associated with Th2 cell re-
sponses. In their study, a prominent role
for eosinophils in chronic colitis has been
identified, which is regulated by GM-CSF
derived from Th17 cells (Griseri et al.,
2015).
Using both acute infectious models
of colitis and a chronic T cell transfer
model, Griseri et al. have demonstrated
that colonic inflammation drives eosino-
poiesis. Eosinophil expansion in the
bone marrow is directly associated with
increased numbers of gut-homing eosin-
ophils released into the circulation and
the number of activated infiltrating eosin-
ophils in the colon. In the colon, eosinophil
mediated damage was driven through
the release of peroxidase as disease
was ameliorated by treatment with resor-
cinol (a potent eosinophil peroxidase
inhibitor). The increase in the number of
bone marrow eosinophils during colitis
was dependent on signaling through the
bc receptor and loss of this signaling
pathway not only decreased eosinopoie-
sis but also markedly reduced colonic
eosinophil infiltration and the severitynity 43, July 21, 2015 ª2015 Elsevier Inc. 7
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Figure 1. The Role of Eosinophils in IL-23-GM-CSF-Eosinophil-Driven Inflammation
IL-5 is the major mediator of eosinophilic disease in allergy. IL-5 promotes eosinophil release from the
bone marrow and enhances eosinophil response to eotaxin while Th2 cell cytokines sustain eosinophil
activation at the mucosa. In contrast, during colitis, IL-5 is required for eosinophil trafficking to the intes-
tinal mucosa but eosinophil activation is sustained by GM-CSF secreted from Th17 cells.
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Previewsof disease. Further investigations using
both blockade of IL-5 and depletion of eo-
sinophils demonstrated that, in contrast
to neutrophils, eosinophils were the major
effector cells determining the severity of
colonic inflammation. These results iden-
tify a previously unappreciated role for eo-
sinophils in driving intestinal inflammation
associated with IBD.8 Immunity 43, July 21, 2015 ª2015 ElsevierThis may seem paradoxical because
neutrophil infiltration appears indepen-
dent of Th cell skewing, whereas eosino-
phil activation and/or recruitment is driven
by a Th2 cell phenotype that is not nor-
mally associated with CD and only loosely
associated with UC. Addressing this, Gri-
seri et al. showed that although IL-5 was
required for eosinophil gut homing (andInc.homeostatic regulation), GM-CSF pro-
duced by CD4+ T cells was responsible
for sustaining eosinophil activation during
colitis and increased expression of the
barrier-dysregulating cytokines, TNF-a
and IL-13, in eosinophils. Recent work in
experimental autoimmune encephalomy-
elitis models have identified an IL-23-
Th17 cell feedback loop, whereby IL-23,
which sustains populations of IL-17-pro-
ducing Th17 cells, also induces GM-CSF
secretion by Th17 cells (El-Behi et al.,
2011). GM-CSF then induces further IL-
23 secretion by antigen-presenting cells,
which sustains chronic, pro-inflammatory
Th17 cell responses. Because Th17 cells
are present in both CD and UC, this might
explain the paradox, with eosinophilia
sustained by Th17 cell signaling and not
Th2 cell-type cytokines, as is the case in
allergy (Figure 1).
The findings of Griseri et al. have a
number of important implications for
our understanding of IBD chronicity,
which warrant further investigation. Un-
like murine models, most cases of IBD
are identified well into the course of
disease. Numbers of activated eosino-
phils in the intestinal mucosa of pa-
tients with active IBD are higher than
healthy individuals. However, increased
levels are not always associated with
active disease as studies with both UC
and CD patients with quiescent disease
have identified similar elevated intestinal
eosinophil populations (some studies
even suggesting increased activation
during quiescence) (Lampinen et al.,
2005). This has been interpreted as a
role for eosinophils in IBD tissue repair,
but it might also suggest an imbalance
in leukocyte homeostasis. Thus, there
is the possibility that these eosinophils,
on exposure to Th17-driven GM-CSF,
contribute to relapse in IBD and their
mediators drive IBD chronicity.
There are number of clinical observa-
tions regarding both eosinophils and
the role of GM-CSF in IBD that will need
to be addressed to fully understand the
significance of these cells in pathogen-
esis. For instance, activated eosinophils
are also abundant in the terminal ileum
of UC patients, where disease is mild
and attributed to ‘‘backwash’’ of the
caecal contents into the ileum (Lampinen
et al., 2005). Also of interest, defects
in GM-CSF pathways have been previ-
ously investigated in IBD patients and
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Previewsrecombinant GM-CSF has been trialed as
a treatment for IBD, with a high incidence
of adverse effects offsetting the reduction
of disease activity. Auto-antibodies to
GM-CSF have been detected in patients
with ileal CD and bc receptor expres-
sion on granulocytes and monocytes is
repressed in patients with IBD, particu-
larly UC patients, collectively suggesting
that GM-CSF-bc signaling is suboptimal
in IBD (Goldstein et al., 2011). How these
past findings play into the role of the IL-
23-GM-CSF-eosinophil axis in IBD, is
unclear. Disease heterogeneity and the
different roles for IL-23 that are observed
in IBD subtypes are likely to be important
in this respect (Kobayashi et al., 2008).
However, once validated in specific sub-
groups (endotypes) of patients, these
findings are likely to offer significant ad-
vances in IBD therapies. Anti-IL-5 thera-
pies are already in advanced stages of
clinical trials for eosinophilic disease and
allergy and are readily transferrable to
IBD management. Similarly, anti-IL-23
monoclonal therapies are in clinical trials
for IBD and eliminating the Th17 cell-
eosinophil axis may prove more effective
than anti-TNF-a therapies. A more simple
therapeutic approach might be inhibitingeosinophil peroxidase (EPO) with antioxi-
dants and thus limiting the major factor
inducing the lesions observed in these
studies. Of note, rectal administration
of vitamin E, a potent anti-oxidant, has
shown some efficacy in mild-moderate
ulcerative colitis (Mirbagheri et al., 2008)
and ironically, inhibition of peroxidase ac-
tivity by the free-radical scavenging prop-
erties of cigarette smoke might explain
the reported beneficial effects of smoking
in UC patients because cigarette smoke
can directly inhibit EPO activity. However,
human IBD is complex and there is likely
to be redundancy across multiple effector
pathways that operate in parallel. The
findings of Griseri et al. might nonetheless
lead to significant advances in our under-
standing of immunopathology, chronicity,
and distinction of phenotypic differences
in IBD subtypes. Whether these findings
also extend to Th17-mediated diseases
in other organs will be of considerable
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Passenger mutations specific to particular mouse strains can distort experimental outcomes. In this issue of
Immunity, VandenBerghe et al. (2015) demonstrate that passengermutations are frequent inmost genetically
engineered congenic mice and persist even after extensive backcrossing.An impressive number of genetically
modified mice have been created since
the techniques for gene targeting in mice
were established in the 1980s by the
2007 Nobel Laureates Mario Capecchi,
Oliver Smithies, and Martin Evans. To
date, at least 11,000 genes have beenspecifically deleted or inactivated in
inbred mice (Hall et al., 2009). Moreover,
institutions like the International Mouse
Phenotype Consortium (IMPC), the Texas
A&M Institute for Genomic Medicine
(TIGM), and the EUCOMMTOOL Project
are engaged in generating collectionsof genetically engineered mutants that
include genetic ablations for all of the
roughly 25,000 protein-coding genes in
the mouse. The comparison of congenic
mice, one bearing a targeted mutation
and one retaining the wild-type (WT) allele
of the gene of interest, is a critical toolnity 43, July 21, 2015 ª2015 Elsevier Inc. 9
